Chemoprevention in barrett's esophagus

Journal of Gastrointestinal Cancer

Volumn 38, Issue 1, 2007, Pages 1-9

  Ilyas, Sumera ^a   Demars, Cathrine J ^a   Buttar, Navtej S ^a,b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Adenocarcinoma of esophagus; Barrett's esophagus; Carcinogenesis; Chemoprevention; Signaling

Indexed keywords

ACETYLSALICYLIC ACID; ALITRETINOIN; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BORTEZOMIB; BUTYROLACTONE; CALCIUM; CAROTENOID; CELECOXIB; DEOXYCYTIDINE; EFLORNITHINE; ESOMEPRAZOLE; FLAVOPIRIDOL; FOLIC ACID; INFLIXIMAB; MATUZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROGUAIARETIC ACID; OLOMOUCINE; RETINOID DERIVATIVE; ROFECOXIB; ROSCOVITINE; S ADENOSYLMETHIONINE; SELENIUM; SOYBEAN PROTEIN; SULINDAC; TRASTUZUMAB; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

AMINO ACID METABOLISM; BARRETT ESOPHAGUS; BODY MASS; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CELL GROWTH; CELL IMMORTALIZATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIET THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; DYSPLASIA; EARLY DIAGNOSIS; ESOPHAGEAL ADENOCARCINOMA; HIGH FIBER DIET; HUMAN; HYPERGASTRINEMIA; LOW DRUG DOSE; NONHUMAN; OBESITY; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SMOKING; STOMACH ACID; TEA; ANIMAL; METHODOLOGY; PRECANCER;

ANIMALS; BARRETT ESOPHAGUS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; HUMANS; PRECANCEROUS CONDITIONS;

EID: 59149087661     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-007-9006-7     Document Type: Review

References (81)

1. SJ Spechler 1987 Adenocarcinoma in Barrett's esophagus Compr Ther. 13 57 60
2. AJ Cameron 1997 Barrett's esophagus: does the incidence of adenocarcinoma matter? Am J Gastroenterol. 92 193 4
3. KK Wang 2005 Current strategies in the management of Barrett's esophagus Curr Gastroenterol Rep. 7 196 201 (Pubitemid 40916399)
4. P Thomas C Doddoli P Lienne N Morati X Thirion L Garbe R Giudicelli P Fuentes 1997 Changing patterns and surgical results in adenocarcinoma of the oesophagus Br J Surg. 84 119 25
5. J Lagergren R Bergstrom A Lindgren O Nyren 1999 Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma N Engl J Med. 340 825 31
6. G Champion JE Richter MF Vaezi S Singh R Alexander 1994 Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus Gastroenterology. 107 747 54
7. HJ Stein WK Kauer H Feussner JR Siewert 1998 Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nissen fundoplication J Gastrointest Surg. 2 333 41
8. WH Chow WJ Blot TL Vaughan HA Risch MD Gammon JL Stanford R Dubrow JB Schoenberg ST Mayne DC Farrow 1998 Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia J Natl Cancer Inst 90 150 5
9. J Lagergren R Bergstrom O Nyren 1999 Association between body mass and adenocarcinoma of the esophagus and gastric cardia Ann Intern Med. 130 883 90
10. LS Engel WH Chow TL Vaughan MD Gammon HA Risch JL Stanford JB Schoenberg ST Mayne R Dubrow H Rotterdam 2003 Population attributable risks of esophageal and gastric cancers J Natl Cancer Inst. 95 1404 13
11. EE Calle R Kaaks 2004 Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms Nat Rev Cancer 4 579 91 summarizes the role of diet and obesity in the development of esophageal adenocarcinoma in Barrett's mucosa.
12. SD Mark YL Qiao SM Dawsey YP Wu H Katki EW Gunter JF Fraumeni Jr WJ Blot ZW Dong PR Taylor 2000 Prospective study of serum selenium levels and incident esophageal and gastric cancers J Natl Cancer Inst. 92 1753 63
13. MD Gammon JB Schoenberg H Ahsan HA Risch TL Vaughan WH Chow H Rotterdam AB West R Dubrow JL Stanford 1997 Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia J Natl Cancer Inst. 89 1277 84
14. K Iijima E Henry A Moriya A Wirz AW Kelman KE McColl 2002 Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction Gastroenterology. 122 1248 57
15. NS Buttar KK Wang 2004 Mechanisms of diseases: carcinogenesis in Barrett's esophagus Nat Clin Pract Gastroenterol Hepatol. 1 106 12
16. GA Sarosi Jr K Jaiswal E Herndon C Lopez-Guzman SJ Spechler RF Souza 2005 Acid increases MAPK-mediated proliferation in Barrett's esophageal adenocarcinoma cells via intracellular acidification through a Cl-/HCO3-exchanger Am J Physiol Gastrointest Liver Physiol. 289 G991 7 novel information on the mechanisms underlying acid induced procarcinogenic signaling.
17. RF Souza K Shewmake LS Terada SJ Spechler 2002 Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus Gastroenterology. 122 299 307 (Pubitemid 34126346)
18. BS Kaur R Ouatu-Lascar MB Omary G Triadafilopoulos 2000 Bile salts induce or blunt cell proliferation in Barrett's esophagus in an acid-dependent fashion Am J Physiol Gastrointest Liver Physiol. 278 G1000 9
19. F Zhang NK Altorki YC Wu RA Soslow K Subbaramaiah AJ Dannenberg 2001 Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids Gastroenterology. 121 1391 9
20. X Chen YW Ding G Yang F Bondoc MJ Lee CS Yang 2000 Oxidative damage in an esophageal adenocarcinoma model with rats Carcinogenesis. 21 257 63
21. KT Wilson S Fu KS Ramanujam SJ Meltzer 1998 Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas Cancer Res 58 2929 34
22. EI Sihvo JT Salminen TK Rantanen OJ Ramo M Ahotupa M Farkkila MI Auvinen JA Salo 2002 Oxidative stress has a role in malignant transformation in Barrett's oesophagus Int J Cancer. 102 551 5
23. NS Buttar MA Anderson KK Krishnadath LS Lutzke PK Nijhawan KK Wang 2000 Chemopreventive potential of selective cyclooxygenase-2 (COX-2) inhibition in Barrett's epithelium: an in-vitro study Gastroenterology. 118 P23
24. NS Buttar 2004 Effect of green tea polyphenol on signaling pathways asociated with esophageal adenocarcinoma in an animal model Gastroenterology. 126 A 47
25. CP Wild LJ Hardie 2003 Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat Rev Cancer. 3 676 84
26. S Iravani HQ Zhang ZQ Yuan JQ Cheng RC Karl R Jove D Coppola 2003 Modification of insulin-like growth factor 1 receptor, c-Src, and Bcl-XL protein expression during the progression of Barrett's neoplasia Hum Pathol. 34 975 82
27. D Coppola A Ferber M Miura C Sell C D'Ambrosio R Rubin R Baserga 1994 A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor Mol Cell Biol. 14 4588 95
28. T Iwao A Toyonaga S Kuboyama K Tanikawa 1995 Effects of omeprazole and lansoprazole on fasting and postprandial serum gastrin and serum pepsinogen A and C Hepato-Gastroenterology. 42 677 82
29. CR Haigh SE Attwood DG Thompson JA Jankowski CM Kirton DM Pritchard A Varro R Dimaline 2003 Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor Gastroenterology. 124 615 25 see comment
30. SI Abdalla P Lao-Sirieix MR Novelli LB Lovat IR Sanderson RC Fitzgerald 2004 Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis Clin Cancer Res. 10 4784 92
31. RH Liu JH Hotchkiss 1995 Potential genotoxicity of chronically elevated nitric oxide: a review Mutat Res. 339 73 89
32. SJ Hughes MA Morse CM Weghorst H Kim PB Watkins FP Guengerich MB Orringer DG Beer 1999 Cytochromes P450 are expressed in proliferating cells in Barrett's metaplasia Neoplasia. 1 145 53
33. J Jankowski D Hopwood R Pringle KG Wormsley 1993 Increased expression of epidermal growth factor receptors in Barrett's esophagus associated with alkaline reflux: a putative model for carcinogenesis Am J Gastroenterol. 88 402 8
34. MJ Brito MI Filipe J Linehan J Jankowski 1995 Association of transforming growth factor alpha (TGFA) and its precursors with malignant change in Barrett's epithelium: biological and clinical variables Int J Cancer. 60 27 32
35. MT Barrett CA Sanchez PC Galipeau K Neshat M Emond BJ Reid 1996 Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus Oncogene. 13 1867 73
36. M Umansky W Yasui A Hallak S Brill I Shapira Z Halpern H Hibshoosh J Rattan S Meltzer E Tahara 2001 Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus Oncogene. 20 7987 91
37. L Garrigue-Antar RF Souza VF Vellucci SJ Meltzer M Reiss 1996 Loss of transforming growth factor-beta type II receptor gene expression in primary human esophageal cancer Lab Invest. 75 263 72
38. KK Krishnadath BJ Reid KK Wang 2001 Biomarkers in Barrett esophagus Mayo Clin Proc. 76 438 46
39. M Younes J Lechago A Ertan D Finnie A Younes 2000 Decreased expression of Fas (CD95/APO1) associated with goblet cell metaplasia in Barrett's esophagus Human Pathol. 31 434 88
40. RV Lord PI Tsai KD Danenberg JH Peters TR Demeester DD Tsao-Wei S Groshen D Salonga JM Park PF Crookes 2001 Retinoic acid receptor-alpha messenger RNA expression is increased and retinoic acid receptor-gamma expression is decreased in Barrett's intestinal metaplasia, dysplasia, adenocarcinoma sequence Surgery. 129 267 76
41. W Zhang A Rashid H Wu XC Xu 2001 Differential expression of retinoic acid receptors and p53 protein in normal, premalignant, and malignant esophageal tissues J Cancer Res Clin Oncol. 127 237 42
42. K Hormi-Carver LA Feagins SJ Spechler RF Souza 2007 All trans-retinoic acid induces apoptosis via p38 and caspase pathways in metaplastic Barrett's cells Am J Physiol- Gastrointest Liver Physiol. 292 G18 27 Defines a novel cancer prevention target.
43. CP Morales EL Lee JW Shay 1998 In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma Cancer. 83 652 9
44. RE Sampliner 1998 Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus. The practice parameters committee of the American college of gastroenterology Am J Gastroenterol. 93 1028 32
45. KK Wang M Wongkeesong NS Buttar 2005 American gastroenterological association medical position statement: Role of the gastroenterologist in the management of esophageal carcinoma Gastroenterology. 128 1468 70 current management recommendations by the American Gastroenterological Association.
46. SJ Spechler 2001 Screening and surveillance for complications related to gastroesophageal reflux disease Am J Med. 111 130S 6S
47. BJ Reid RC Haggitt CE Rubin G Roth CM Surawicz G Van Belle K Lewin WM Weinstein DA Antonioli H Goldman 1988 Observer variation in the diagnosis of dysplasia in Barrett's esophagus Human Pathol. 19 166 178 (Pubitemid 18091022)
48. BJ Reid PL Blount PS Rabinovitch 2003 Biomarkers in Barrett's esophagus Gastrointest Endosc Clin N Am. 13 369 97
49. RC Fitzgerald 2005 Genetics and prevention of oesophageal adenocarcinoma Recent Results Cancer Res. 166 35 46 summarizes the genetics of esophageal adenocarcinoma in Barrett's mucosa.
50. P Lao-Sirieix A Roy C Worrall SL Vowler S Gardiner RC Fitzgerald 2006 Effect of acid suppression on molecular predictors for esophageal cancer Cancer Epidemiol Biomark Prev. 15 288 93
51. PC Konturek A Nikiforuk J Kania M Raithel EG Hahn S Muhldorfer 2004 Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors Dig Dis Sci. 49 1075 83
52. M Madhavan C Demars S Papenfuss G Prasad L Lutzke M Anderson LWK Song K Wang N Buttar 2006 Pge2 regulation by cytosolic pla2 alpha, a potential non-COX-2 chemopreventive target, during carcinogenesis in Barrett's mucosa Gastroenterology. 130 A77
53. MK Hong WB Laskin BE Herman MH Johnston JJ Vargo SM Steinberg CJ Allegra PG Johnston 1995 Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus Cancer. 75 423 29
54. GY Lauwers O Kandemir PS Kubilis GV Scott 1997 Cellular kinetics in Barrett's epithelium carcinogenic sequence: roles of apoptosis, bcl-2 protein, and cellular proliferation. Mod Path. 10 1201 8
55. P Sharma K McQuaid J Dent MB Fennerty R Sampliner S Spechler A Cameron D Corley G Falk J Goldblum 2004 A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop Gastroenterology. 127 310 30 expert opinion in the management of Barrett's esophagus.
56. TG Schell 2004 Acid suppression and adenocarcinoma of the esophagus: cause or cure? Am J Gastroenterol. 99 1884 6
57. HB El-Serag TV Aguirre S Davis M Kuebeler A Bhattacharyya RE Sampliner 2004 Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus Am J Gastroenterol. 99 1877 83 explores the effect of acid suppression on the development of dysplasia in Barrett's mucosa.
58. LC Hillman L Chiragakis B Shadbolt GL Kaye AC Clarke 2004 Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus Med J Aust. 180 387 91 Explores the effect of acid suppression on the development of dysplasiaand cancer in Barrett's mucosa
59. R Ouatu-Lascar RC Fitzgerald G Triadafilopoulos 1999 Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression Gastroenterology. 117 327 35 (see comments).
60. DC Farrow TL Vaughan PD Hansten JL Stanford HA Risch MD Gammon WH Chow R Dubrow H Ahsan ST Mayne 1998 Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer Cancer Epidemiol Biomark Prev. 7 97 102 (Pubitemid 28109839)
61. DA Corley K Kerlikowske R Verma P Buffler 2003 Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis Gastroenterology. 124 147 56
62. M Li R Lotan B Levin E Tahara SM Lippman XC Xu 2000 Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention Cancer Epidemiol Biomark Prev. 9 545 9
63. TL Vaughan LM Dong PL Blount K Ayub RD Odze CA Sanchez PS Rabinovitch BJ Reid 2005 Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study Lancet Oncol. 6 945 52 explores the effect of NSAIDs on the development of cancer in Barrett's mucosa
64. NS Buttar KK Wang O Leontovich JY Westcott RJ Pacifico MA Anderson KK Krishnadath LS Lutzke LJ Burgart 2002 Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus Gastroenterology. 122 1101 12
65. BS Kaur N Khamnehei M Iravani SS Namburu O Lin G Triadafilopoulos 2002 Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus Gastroenterology. 123 60 7
66. X Chen N Li S Wang J Hong M Fang J Yousselfson P Yang RA Newman RA Lubet CS Yang 2002 Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and alpha-difluoromethylornithine on tumorigenesis in a rat surgical model Carcinogenesis. 23 2095 102
67. RE Marshall A Anggiansah WJ Owen 1997 Bile in the oesophagus: clinical relevance and ambulatory detection Br J Surg. 84 21 28 (Pubitemid 27033094)
68. MF Vaezi JE Richter 1995 Synergism of acid and duodenogastroesophageal reflux in complicated Barrett's esophagus Surgery. 117 699 704
69. D Nehra P Howell CP Williams JK Pye J Beynon 1999 Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity Gut. 44 598 602 see comments (Pubitemid 29195903)
70. KD Lindor RA Jorgensen ML Anderson GJ Gores AF Hofmann NF LaRusso 1996 Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study Am J Gastroenterol. 91 511 5
71. Y Hattori Y Murakami S Hattori H Kuroda K Kasai S Shimoda 1996 Ursodeoxycholic acid inhibits the induction of nitric oxide synthase Eur J Pharmacol. 300 147 50
72. P Sahbaie P Siersema S Sood B Kaur AF Hofmann G Triadafilopoulos 2004 Ursodeoxycholic acid (UDCA) increases proliferation and does not show promise as a chemoprevention agent in Barrett's esophagus Gastroenterology. 126 A181
73. JK Lin YC Liang SY Lin-Shiau 1999 Cancer chemoprevention by tea polyphenols through mitotic signal transduction blockade Biochem Pharmacol. 58 911 5
74. DeMars C BN, Wang K, Mittal V, Lutzke L. Chemopreventive effects of green tea polyphenol on Barrett's esophagus associated subepithelial stromal cells. Cancer Res. 2003;AACR 2003 Frontiers in Cancer Prevention Research (Abstract).
75. V Mittal NS Buttar C DeMars KK Wang LM Wong K Song SM Papenfuss M Anderson L Lutzke A Ross 2004 Effect of green tea polyphenol on signaling pathways associated with esophageal adenocarcinoma in an animal model Gastroenterology. 126 A47
76. E Bollschweiler E Wolfgarten T Nowroth U Rosendahl SP Monig AH Holscher 2002 Vitamin intake and risk of subtypes of esophageal cancer in Germany J Cancer Res Clin Oncol 128 575 80
77. X Chen SS Mikhail YW Ding G Yang F Bondoc CS Yang 2000 Effects of vitamin E and selenium supplementation on esophageal adenocarcinogenesis in a surgical model with rats Carcinogenesis 21 1531 6
78. G Triadafilopoulos B Kaur S Sood B Traxler D Levine A Weston 2006 The effects of esomeprazole combined with aspirin or rofecoxib on prostaglandin E2 production in patients with Barrett's oesophagus Aliment Pharmacol Ther. 23 997 1005 explores the effect of acid suppression and Aspirin on the pro-neoplastic signaling in Barrett's mucosa
79. EI Heath MI Canto S Piantadosi E Montgomery WM Weinstein JG Herman AJ Dannenberg VW Yang AO Shar E Hawk 2007 Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial J Natl Cancer Inst. 99 545 57
80. EJ Topol 2004 Failing the public health-rofecoxib, Merck, and the FDA N Engl J Med. 351 1707 9
81. J Jankowski P Sharma 2004 Review article: approaches to Barrett's oesophagus treatment-the role of proton pump inhibitors and other interventions Aliment Pharmacol Ther. 19 Suppl 1 54 9